Senolytic Treatment Attenuates Global Ischemic Brain Injury and Enhances Cognitive Recovery by Targeting Mitochondria
Open Access
- 18 June 2025
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-17
Abstract
The benefits of senolytic therapy have been known in a series of age-related diseases, whereas its potential roles in global cerebral ischemic (GCI) brain injury remain unexplored. In current study, we aim to investigate the effects of combined senolytics Dasatinib plus Quercetin (D&Q) treatment in GCI and the underlying mechanisms in a mouse model. We firstly report that 12-week post-GCI D&Q treatment effectively eliminated cellular senescence of astrocytes and microglia in the hippocampus of mice brain, followed by decreased release of the potent inflammatory senescence-associated secretory phenotypes (SASP). Further mechanistic analysis suggested that D&Q administration can effectively regulate mitochondrial function as a critical downstream target. D&Q treatment inhibited GCI-induced mitochondrial fragmentation and maintained mitochondrial integrity. Subsequently, D&Q treatment improved the mitochondrial metabolic function by enhancing mitochondrial cytochrome c oxidase (CCO) activity and ATP production. Moreover, D&Q treatment reversed the decline of mitochondrial antioxidant enzyme SOD2 and reduced the ROS accumulation and suppressed oxidative damage to cellular protein structure. Further investigation indicated D&Q treatment protected the hippocampal neurons after GCI by mitigating the dendritic injury and neuronal apoptotic signaling. Extensive behavioral tests assessed the functional outcomes and showed that D&Q treatment effectively preserved hippocampus-dependent spatial reference memory and recognition memory, and mitigated GCI-induced anxiety and depression levels. Taken together, our study provides leading evidence for the neuroprotective roles of the senolytics D&Q in GCI model and identifies regulation of mitochondrial functions could be the key underlying mechanism. These findings offer novel insights into the potential clinical applications of senolytic agents in therapy. Graphical AbstractKeywords
Funding Information
- 2023 Lianyungang Aging Health Research Project (L202311)
- 2023 Lianyungang Science and Technology Plan Project (23JCYJ015)
- 2023 Doctoral Research Start-up Fund of the First People's Hospital of Lianyungang City (BS202314)
This publication has 88 references indexed in Scilit:
- Tissue Engineering of JAK Inhibitor‐Loaded Hierarchically Biomimetic Nanostructural Scaffold Targeting Cellular Senescence for Aged Bone Defect Repair and Bone RemoldingAdvanced Healthcare Materials, 2023
- Brain age estimation reveals older adults’ accelerated senescence after traumatic brain injuryGeroScience, 2022
- Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathologyCell Reports, 2021
- Mitochondrial dysfunction and cell senescence: deciphering a complex relationshipFEBS Letters, 2019
- Measurement of Reactive Oxygen Species (ROS) and Mitochondrial ROS in AMPK Knockout Mice Blood Vessels2018
- Traumatic brain injury in later life increases risk for Parkinson diseaseAnnals of Neurology, 2015
- Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?Neurotherapeutics, 2015
- Anti-apoptotic and Anti-oxidative Roles of Quercetin After Traumatic Brain InjuryCellular and Molecular Neurobiology, 2014
- Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory NetworkCell, 2008
- Glutamate neurotoxicity in cortical cell culture is calcium dependentNeuroscience Letters, 1985